Impact Factor
2.94
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.81
6,865 total citations
h5-index
103
h5 depth signal
Cited share
11.1%
972 of 8,783
Total citations
6,865
Citation footprint
Metric signal
1.47
External metric anchor
Self-citation
4.9%
337 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United Kingdom
6,711
United States
3,880
Italy
2,938
Germany
2,910
Spain
2,837
Citing Fields of Research
Allergies
11,138
Respiratory Support
7,961
Lung Cancer
4,828
Auto-Inflammatory Disorders
3,453
Cystic Fibrosis
2,410
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
27,098
Articles tracked across the journal lifetime
Indexed publication set
8,783
972 cited publications
Last 12 months
381
31.8 publications/month
Open access share
26.5%
101 OA publications in the last year
Leading citing country
United Kingdom
6,711 citing publications
Leading citing field
Allergies
11,138 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Jan. 1988-
v1n1,Jan. 1988-
Active Coverage
Research Focus & Classification
Indexed Subjects
Allergies
Auto-Inflammatory Disorders
Cardiology
Respiratory Support
Cystic Fibrosis
Lung Cancer
Issuing & Sponsoring Bodies
Contributor
European Society for Clinical Respiratory Physiology
Contributor
European Respiratory Society
Broad Categories
Pulmonary Medicine
Allergies
Cardiology
Cystic Fibrosis
Auto-Inflammatory Disorders
Mycobacterial Diseases
MeSH Descriptors
Respiration
Respiratory Tract Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1183/13993003.01207-2026
Open DOI
Cumulative lifecourse cardiovascular health and interstitial lung abnormalities
02
DOI 10.1183/13993003.00023-2026
Open DOI
Single-cell multi-omics in IPF and COPD: from atlas to impact
Single-cell and spatial multi-omics technologies are transforming our understanding of the normal lung cellular repertoire as well the molecular and cellular networks of chronic lung diseases. In this review we focus on idiopathic pulmon...
03
DOI 10.1183/13993003.00866-2026
Open DOI
A phase 2a study with SPL84: A novel RNA-targeted approach to restore CFTR function in people with CF carrying the 3849+10 kb C→T mutation
Background: The 3849+10 kb C→T mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leads to aberrant splicing and the inclusion of a cryptic exon harboring a premature stop codon, resulting in the production o...
04
DOI 10.1183/13993003.01162-2026
Open DOI
Sputum and oral microbiota profiles are associated with long COVID severity and phenotype post-hospitalisation: a UK multicentre, prospective cohort study
Background: Acute COVID-19 alters the airway microbiota. Whether these changes persist post-COVID-19 and contribute to long COVID is unknown. We aimed to describe the microbiota by long COVID severity and subtype, and identify links with...
05
DOI 10.1183/13993003.00317-2026
Open DOI
Dysregulated NK cell phenotype in exacerbation-prone severe asthma
Background: Natural killer (NK) cell dysfunction and defective inflammation resolution pathways are associated with chronic airway inflammation in asthma. NK cells are targets for regulation by essential polyunsaturated fatty acid-derive...
06
DOI 10.1183/13993003.01186-2026
Open DOI
ERS/ESRS clinical practice guideline for continuous positive airway pressure for the treatment of adult obstructive sleep apnoea
Background: Continuous positive airway pressure (CPAP) is the primary treatment for obstructive sleep apnoea (OSA), although its effectiveness may vary across OSA subtypes. This joint European Respiratory Society (ERS)/European Sleep Res...
07
DOI 10.1183/13993003.01507-2026
Open DOI
Haemodynamic remission and transition off epoprostenol after upfront triple therapy in PAH
Extract Beyond the established treatment goal of low-risk status in pulmonary arterial hypertension (PAH) [1], haemodynamic thresholds for complete and partial remission have recently been proposed as deeper treatment targets [2, 3]. Upf...
08
DOI 10.1183/13993003.00816-2026
Open DOI
Eurotransplant experience with Model for End-Stage Liver Disease standard exceptions for hepatopulmonary syndrome and portopulmonary hypertension
Extract Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PoPH) represent distinct pulmonary vascular complications associated with portal hypertension and end-stage liver disease. While HPS results from intrapulmonary vaso...
09
DOI 10.1183/13993003.00791-2026
Open DOI
Pleuroparenchymal fibroelastosis in a monogenic mitochondrial DNA depletion syndrome
Background: Pleuroparenchymal fibroelastosis (PPFE) is a rare, most often idiopathic fibrotic lung disease with poor prognosis, mainly affecting adults. Biallelic pathogenic variants in the deoxyguanosine kinase gene ( DGUOK ) cause a mi...
10
DOI 10.1183/13993003.00643-2026
Open DOI
GLP-1-based therapies in lung diseases
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for the treatment of type 2 diabetes and obesity, are increasingly recognised as multi-system agents with cardiovascular, renal and anti-inflammatory benefits. Em...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 56 (2020).
Online version contains supplements.
Also issued online.
Articles in English; summaries in English and French.
Issued by the European Society for Clinical Respiratory Physiology, 1988-<2002>; by: European Respiratory Society, <2003->
Formed by the union of: Clinical respiratory physiology, and: European journal of respiratory diseases.